Viva Ma Attendees Director, Strategic Access, Public Affairs, Greater Asia Becton Dickinson Singapore [email protected] www.linkedin.com/in/viva-yan-ma-66261238 Dr. Ma is the Director of Strategic Access, Public Affairs, Greater Asia, in Becton Dickinson (BD), one of the largest global medical device companies. Prior to BD, she worked at Johnson & Johnson and Edwards Lifesciences in several corporate functions including health economics, market access, reimbursement and supply chain. Dr. Ma has dedicated her career to improving the affordability and patient access to innovative diagnostic and therapeutic technologies around the world. As an Executive Committee member for the International Society for Pharmacoeconomics Outcomes Research (ISPOR) Singapore, she is a catalyst in building the health economics and outcomes research capacity for the Asia Pacific region, working closely with research institutions Through her leadership role in HTAi Asia Policy Forum and AmCham Singapore, she is actively driving value-based health care, as well as cross-sector dialogue and partnerships in the health care eco-system. Dr. Ma holds a PhD degree from University of Wyoming; a Postdoctoral certificate from Yale University School of Medicine; a MPH degree from the Johns Hopkins University Bloomberg School of Public Health; and a MBA degree from the Johns Hopkins University Carey Business School. Guy Maddern RP Jepson Professor Of Surgery; HTAi Asia Policy Forum Chair University Of Adelaide Australia [email protected] Professor Guy Maddern is the RP Jepson Professor of Surgery at the University of Adelaide, Director of Research at the Basil Hetzel Institute for Translational Health Research at The Queen Elizabeth Hospital and Director, Surgical Research and Evaluation (incorporating ASERNIP-S) of the Royal Australasian College of Surgeons. He was trained at the University of Adelaide and became a Fellow of the Royal Australasian College of Surgeons in 1989. His clinical interests include the development of techniques to manage metastatic hepatic disease and hepatic approaches to optimise resection options. He has also published widely on new surgical techniques and their introduction into surgical practice. He has over 500 publications in scientific journals, has contributed to over a dozen surgical texts and attracted $65 million of research funding. The evaluation of new technologies and in particular surgical technologies is another area of focus and interest. Under his supervision, ASERNIP-S has been responsible for assessing these technologies before exposing the Australian population to them and has provided this service to the Australian and International community for the past 20 years, and is recognised, nationally and internationally, as the premier surgical innovation assessment group. He is a past President of HTAi and a past Chair of INAHTA. 51
Attendees Lusiana Siti Masytoh Staff Ministry Of Health Indonesia [email protected] @luciana_siti Lusiana Siti Masytoh is the staff from the HTA working team at Centre for Health Financing and Decentralization Policy - Health Policy Agency – Ministry of Health Republic of Indonesia. She has worked with HTA since the establishment of the Indonesian HTA Committee (InaHTAC) in 2014. Active as the InaHTAC secretariat responsible for managing HTA strengthening and development activities, she is also a researcher in several HTA studies. Dominique Milea Value Evidence & Outcome Regional Head GlaxoSmithKline Singapore [email protected] www.linkedin.com/in/dominique-milea-66046414/ Dominique Milea has more than 25 years of experience in the pharmaceutical and healthcare environment both in Europe and Asia. She has worked in the areas of health economics and real world evidence in support of market access for the past 15 years, arriving in Singapore in 2012. She is currently Senior Director for Value Evidence & Outcomes for Asia Pacific at GSK. In this role, Dominique is responsible for developing regional evidence plans to demonstrate the value of GSK assets and for guiding the development of local reimbursement and access strategies. Dominique holds a pharmacy degree from university of Paris V in France, a master degree in Public Health from University of Paris XI, France and a PhD in Health Economics from University of Lyon II, France. 52
Izzuna Mudla Mohamed Ghazali Attendees Head MaHTAS Malaysia [email protected] @IzzunaG linkedin.com/in/izzuna-ghazali-89983a58 Dr. Izzuna Mudla Mohamed Ghazali is the Deputy Director of the Medical Development Division, Ministry of Health Malaysia, and the Head of the Malaysian Health Technology Assessment Section (MaHTAS). She is a Public Health Physician and joined MaHTAS in 2007. She plays a key role in planning and implementation of health technology assessment, development, and implementation of clinical practice guidelines, and was the responsible person to set up horizon scanning of emerging health technologies activity for the Ministry of Health Malaysia. Dr. Izzuna is actively involved at the local and international levels. She is a visiting lecturer at the University of Malaya, University of Science Malaysia, and Cyberjaya University. She is also a member of various committees at the national level including Cluster of Emerging Technologies, Nutritional Research, National Technology Innovation Sandbox, and National Rare Disease Committee. At the international level, she is currently the Chair of the International Society for Pharmacoeconomics and Outcome Research (ISPOR) HTA Roundtable Asia Pacific, Vice President of HTAsiaLink, Regional Coordinator for AsiaScan, the regional group for the Asia Pacific Region of the International Health TechScan (i-HTS), and a member of the organizing committee for HTAi Asia Policy Forum. Kanchan Mukherjee Professor Tata Institute Of Social Sciences (tiss) India [email protected] Dr. Kanchan Mukherjee is a Professor at the Centre for Health Policy, Planning and Management in the School of Health Systems Studies at the Tata Institute of Social Sciences, Mumbai, India. Prof. Mukherjee completed his MBBS and MD from Mumbai. He also has specializations in Public Health (gold medalist), Health Policy and Health Economics. He completed the NIH Fogarty Postdoctoral Fellowship from the University of California, Los Angeles (USA) in HIV/AIDS research. He also completed MSc. in International Health Policy, with distinction in Health Economics from the London School of Economics and Political Science (UK). He has been a recipient of many awards and international fellowships. He was also a visiting faculty at the Karolinska Institute (Sweden) and the University of Liverpool (UK). Prof. Mukherjee has over 20 years of teaching, research and field work experience. He has over 70 publications in the fields of public health, health systems and policy analysis, economic evaluation, Health Technology Assessment, urban health, HIV/AIDS, non-communicable diseases, and healthcare innovations. He is the Founding Convener of the MPH in Health Policy, Economics and Finance (HPEF) programme at TISS, which was started in collaboration with the London School of Economics and Political Science (UK) for capacity building in HTA in India and South Asia. He is a member of the WHO GBD collaborator network, Global Consortium on Public Health Research, International Society for Infectious Diseases, ISPOR, HTAi Asia Policy Forum, HTAsiaLink, Epidemiology Foundation of India. He is also a faculty expert with the Department of Health Research (Government of India) for training scientists in evidence-informed policy making and writing policy briefs. He is an editorial board member of six international journals. 53
Attendees Linda Mundy Scientific Secretariat HTAi Australia [email protected] @Woofie09 www.linkedin.com/in/linda-mundy-b0121531/ Linda has been the Asia Policy Forum’s Scientific Secretariat since 2017. With a background as a bench clinical researcher primarily in obstetrics and gynaecology, she sought a change in direction, running the Australian and New Zealand horizon scanning network on behalf of HealthPACT. In addition to her role in HTAi, Linda now works for the Royal College of Pathologists of Australasia, preparing applications for the public funding of pathology tests. Kwong Ng Chief HTA Officer Agency For Care Effectiveness, Singapore Ministry Of Health Singapore [email protected] Kwong joined MOH from the private sector in June 2015 to help DDMS (HPG) set up Singapore’s national health technology assessment (HTA) agency, the Agency for Care Effectiveness (ACE). He has over 20 years’ experience in healthcare industry across both private and public sectors. He was previously a Regional Director at multinational pharma and device companies (Allergan, Johnson and Johnson) responsible for market access, health economics, pricing, health technology assessment and outcomes research in multiple countries across the Asia Pacific (Australia, New Zealand, China, Taiwan, Korea, Japan and South East Asia). Prior to his move to Singapore, he was based in Australia where he worked for the Australian government critiquing industry submissions for the Pharmaceutical Benefits Advisory Committee (PBAC) (the Australian national HTA Drug Committee). He also previously worked for a non-profit Australian agency in using implementation science and behavioural change theory to improve doctors’ prescribing and patient outcomes. He was trained in pharmacy, health economics and public health in Australia. Currently he has an Adjunct Associate Professor position at the School of Public Health, National University of Singapore. He is managing a team of more than 50 staff across multiple work streams within ACE including evaluation of drugs and medical technologies, value-based pricing, economic modelling, utilisation review and guidance adoption. 54
Yi Ting Ng Attendees Head (planning & Policy) Agency For Care Effectiveness Singapore [email protected] Tuan Viet Nguyen Researcher Health Strategy And Policy Institute Vietnam [email protected] Tuan-Viet Nguyen has 10 years’ working as a researcher for Health Strategy and Policy Institute in Vietnam. He got a master degree in Health Economics, Policy and Law from Erasmus University of Rotterdam in 2017. For HTA topics, he has experienced in several studies related to hepatitis C, HIV, follicular lymphoma, chronic lymphocytic leukemia and hypertension. Besides, provider payment methods, hospital efficiency and patients’ preference are areas of his interest. Due Ong The Researcher Health Strategy And Policy Institute Vietnam [email protected] Dr. Ong The Due is a medical doctor by training. He has been working in the Health Strategy and Policy Institute (Ministry of Health, Vietnam) since 2012. He holds a doctorate in Health Technology Assessment from Mahidol University, Thailand. His major research interests focus on the area of (i) Health Technology Assessment, including Health Economics, Cost-Effectiveness Evaluation, Modelling, Outcomes Research, Evidence Synthesis, and (ii) Health Policy and System Research, focusing on health system at grassroots level, primary health care, non-communicable diseases, health equity, and implementation science. 55
Attendees Wija Oortwijn HTAi President Radboud University Medical Centre Netherlands [email protected] @OortwijnW www.linkedin.com/wija-oortwijn-7510b8b Wija Oortwijn holds a position as senior researcher in the field of global HTA at the Radboud University Medical Centre (Radboudumc) in Nijmegen, the Netherlands. She studied health sciences and holds a PhD in Medicine (priority setting for HTA). She has 30 years of relevant professional experience in HTA and health policy analysis around the globe, with her key expertise including health priority setting, policy evaluation and measuring the impact of research. Since 1992, she has been extensively involved in the development of HTA and health system strengthening around the world. She is a founding member of the Dutch Society for HTA (NVTAG) and the international HTA Society (HTAi). Currently, she is President of HTAi, co-chairing the HTAi-ISPOR Good Practices Task Force on deliberative processes for HTA, co-chair of the HTAi-DIA working group on uncertainty in HTA, and she is associate editor of the International Journal of Technology Assessment in Health Care. Alicia Powers Manager, Events HTAi Canada [email protected] Alicia (known as Ali) is an event organizer with over 15 years of experience in every aspect of events management, including large and small conference management in national and international locations, workshop development, and annual gala productions. Ali’s experience also includes event work with professional sports teams, universities, hospital foundations, and health technology startup organizations. Before joining HTAi, Ali held a position in the Corporate Communications and Marketing department at Alberta Innovates. She has also executed over 60 weddings over the past decade and was recently shortlisted in the “future leader” category at the Edmonton Event Awards. Ali also sits on the Board of Directors for the International Live Events Association (ILEA – Edmonton Chapter). 56
Hana Price Attendees Senior Coordinator, Events HTAi Canada [email protected] www.linkedin.com/in/hana-price-34930143/ Hana Price has over 10 years of experience in Event Management & Coordination, as well as Communications, Administration, Travel and Project Coordination. Throughout her career, Hana has held positions in various roles in the not-for-profit sector, including holding a long-time role of Event Coordinator with the Institute of Health Economics and taking on various project coordination roles and communication projects. Hana has organized several types of corporate events, such as Consensus Development Conferences, Roundtables, Forums, Webinars, Policy Forums and Annual Meetings, both locally, nationally, and internationally. Virginia Priest Director HEMA APAC Boston Scientific New Zealand [email protected] www.linkedin.com/in/virginia-hall-priest-57010942/ Virginia is our Asia Pacific HEMA Director at Boston Scientific. She leads a team of access professionals in developing strategies and evidence to support patient access across the region. Virginia has >15 years’ experience in health economics and market access for pharmaceuticals and medical devices for both Government and industry. Prior to Boston Scientific Virginia assessed medicines for public-sector reimbursement for both the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia and PHARMAC, the New Zealand’s Pharmaceutical Management Agency. She has worked across a broad range of therapeutic areas including oncology, infection, auto-immune diseases, ophthalmology, smoking cessation, mental health, cardiovascular and renal disease. Janil Puthucheary Senior Minister Of State Ministry Of Communications & Information And Ministry Of Health Singapore Dr Janil Puthucheary, 49, was elected Member of Parliament in 2011. He is currently Senior Minister of State, Ministry of Communications and Information, and Ministry of Health. He chairs OnePeople.sg, which works to promote racial harmony in Singapore. His political roles include Chair of Young PAP (the youth wing of the People's Action Party), and Whip. 57
Attendees Raoh-Fang Pwu Director, TWNHCP Office Ministry Of Health And Welfare Taiwan [email protected] @jasminepwu www.linkedin.com/in/raoh-fang-jasmine-pwu-8031869/ Raoh-Fang (Jasmine) Pwu, PhD, is the Director, National Hepatitis C Program Office, Ministry of Health and Welfare in Taiwan. She also is adjunct Assistant Professor at the Taipei Medical University. Trained as an epidemiologist at College of Public Health, National Taiwan University, Dr Pwu has gained expertise in research designs and analysis of large/claims database early in her career. Along the research path she found economic evaluations in healthcare quite interesting and became determined to pursue a career in this field. She is one of the first researchers to excel in modeling cost-effectiveness of medicines and public health interventions in Taiwan. She gives lectures and advises students on analytic-decision models and their applications. Since completing her master thesis, she has over 20 years of experience in research and application in health economics and outcomes research (HEOR) studies. Dr Pwu and several of her college colleagues founded a consulting company specializing in clinical/ epidemiological research design and data analysis in 1999. However, when the Taiwan government asked her to develop a health technology assessment (HTA) system in Taiwan in 2007, she began working for the Division of HTA, Center for Drug Evaluation. She became the second Director of the HTA Division since 2009. In this role, she and her team have developed a strong HTA system and research. Dr Pwu is an enthusiastic collaborator. Therefore, she welcomes any chance to serve the Society. She served on the INAHTA Board from 2010-2012. She and her HTA colleagues from Thailand and Korea created HTAsiaLink in 2010 and she served as their President from 2014 to 2016. Dr Pwu has been an ISPOR member since 2001 and served as the Board of Director for 3 years (2018-2021). Zhiyu Qiu Govt Affairs & Market Access Senior Specialist Medtronic United States [email protected] Bacher of Science (Pharm)(Hons) Master of Science (HTA and reimbursement) 58
Patrick Wincy Reyes Attendees Supervising Health Program Officer Department Of Health Philippines [email protected] www.linkedin.com/in/patrick-wincy-reyes-4558a2124/ Budding statistician in the field of health technology assessment Sheena Jasley Samonte Supervising Health Program Officer Department of Health (Philippines) - HTA Division Philippines [email protected] linkedin.com/in/sheenajasley sheenajasley Ms. Sheena Jasley G. Samonte is a licensed pharmacist who graduated from the University of the Philippines Manila, the country's premier health sciences center. She has been with the Department of Health - Health Technology Assessment Division (DOH - HTAD) since it started its operations in 2019. She contributed to the crafting of the Administrative Order 2020-0041 or “The New Implementing Guidelines on Health Technology Assessment to Guide Funding Allocation and Coverage Decisions in support of Universal Health Care” and its annexes, the HTA Process and Methods Guides, which aim to define the overall framework to institutionalize and implement HTA as a priority setting mechanism that shall be recommendatory to guide DOH and PhilHealth on all coverage and funding allocation decisions. Alongside this, she has also been supporting the DOH - HTAD in its numerous milestones and ways forward for the past 3 years. At present, she is the Unit Head of the Technical Secretariat of the DOH - HTAD which is responsible for implementing the HTA process as a whole, and providing the HTA Council with the proper advice and resources for discharging its duties under the UHC Law. Sumitra Shantakumar Regional Vaccines Epidemiology & Health Economics Head GSK Singapore [email protected] Sumitra heads GSK's Regional Vaccines Epidemiology & Health Economics team for Greater China and Intercontinental. 59
Attendees Hui Sin Teo Market Access And Government Relations Leader, Greater Asia Becton, Dickinson and Company Singapore [email protected] www.linkedin.com/in/hui-sin-teo Hui Sin is a health policy and public affairs specialist with experience in national government and international development sectors, and in the medical technology industry. She has authored health system and financing assessments, pharmaceutical policy analysis, and is seasoned in stakeholder management and communication, and international development. Hui Sin holds a Master of Public Policy from Harvard Kennedy School. Joice Valentim Global HTA Strategy Lead ROCHE Pharma Switzerland [email protected] www.linkedin.com/in/joicevalentim-phd/ Joice Valentim is Global HTA Strategy Lead, and prior Global Access Evidence Lead and Latin America HTA Lead, at Roche Pharma. Joice is responsible for the Global HTA Strategy, leading the organization towards an unified HTA position to partner with stakeholders for early, holistic and deliberative HTA, locally appropriate and innovation-ready. Joice represents Roche at efpia, CIRS, PhRMA, and HTAi, and for academia. For HTAi, currently collaborating with the HTAi GPF and HTAi Annual Meeting committees. Before, in the HTAi LA PF committee, ISPOR Industry Committee as LA president, and FIFARMA. She was an invited professor at the University of São Paulo (MBA HTA, Health Economics/FIPE), a reviewer of scientific journals and author of articles and abstracts on HTA and HE. Prior to Roche, she worked at Novartis, and universities in Brazil as professor and researcher, including projects for the Ministry of Health (HTA for inclusion of new vaccines into the National Immunization Program/PNI) and the National Regulatory Agency for Private Health Insurance and Plans (ANS) of Brazil, PAHO, IDB and the World Bank. Economist, Joice holds a master degree in Economics and a doctorate degree in Preventive Medicine from the University of São Paulo. 60
Julie Van Bavel Attendees Exec. Director Core Regional, Ap MSD Australia [email protected] Julie has more than 20 years of health care evaluation experience in the pharmaceutical industry with related expertise in comparative effectiveness, HTA, health economics, outcomes research, and policy research and analysis. She has held diverse roles at the country, regional and global levels and has experience across numerous geographies including Australia, the US, Europe and Asia Pacific. Julie is particularly interested in conducting research to inform healthcare decision-making Most recently, Julie was responsible for the design and creation of a health and budget impact tool for oncology and a multi- year collaborative research project on outcome-based risk sharing agreements with United Healthcare in the U.S. Julie received her Master of Veterinary Science from Melbourne University and Masters in Public Health from Sydney University. Ly Vichea Ravouth Director Planning and Health Information Department, Ministry of Health Cambodia [email protected] Ly Vichea Ravouth (MD), Cambodian nationality. Experienced Department of Planning and Health Information Director. Skilled in Strategic and Planning Development, monitoring and reporting on health sector, Health policy development, Focal point in H-EQIP responsible for Monitoring and Evaluation, Member of Public Financial Management Reform of Ministry of Health, Member of Inter-Ministries Working Group for monitoring and evaluation on the Implementation of NSDP and CSDG, Member in Inter-Ministries Working Group on Devolvement and Monitoring of Policy Population. 61
Attendees Hwee Lin Wee Associate Professor National University Of Singapore Singapore [email protected] www.linkedin.com/in/hwee-lin-wee-27a86547 Ap/P Hwee-Lin Wee is joint Associate Professor at the Saw Swee Hock School of Public Health and Department of Pharmacy, Faculty of Science at the National University of Singapore. She contributes actively to the local and international academic communities. Internationally, she is a member of the International Society for Pharmacoeconomics and Outcomes Research Health Sciences Policy Council, and member of the International Editorial Advisory Board for Journal of Patient Reported Outcomes, member of the National Advisory Committee on Cancer. A/P Wee’s current work focuses on the use of real world evidence in health technology assessments. Budi Wiweko Chairman Indonesia Health Technology Assessment Committee, Ministry Of Health Republic Of Indonesia [email protected] Professor Budi Wiweko, MD, OG (REI), MPH, PhD is The Immediate Past President of the Asia Pacific Initiative on Reproduction (ASPIRE) for 2018 – 2020 and a vice director of the Indonesian Medical Education and Research Institute Faculty of Medicine Universitas Indonesia (IMERI FKUI). Now he is the general secretary of the Asian Society for Fertility Preservation (ASFP) and the chairman of the Indonesia Health Technology Assessment Committee (InaHTAC), Ministry of Health Republic of Indonesia. He is also a member of the Indonesia National Academic of Sciences since 2020. In Indonesia, he serves as The Immediate Past President of the Indonesian Association for IVF (IAIVF) and a General Secretary for the Indonesian Society for Obstetrics and Gynecology (POGI). He is also the chairman of the Medical Education and Medical Practice Development of the Indonesian Medical Association (IMA). 62
Yeh-ping Wong Attendees Senior Assistant Director Agency For Care Effectiveness Singapore [email protected] I am trained in Environmental Engineering and started my career in the National Environment Agency, Singapore where I had worked on environmental policy and stakeholders’ and public engagements and education. With this knowledge and experience, I moved to the Agency for Care Effectiveness (ACE), under the Ministry of Health, Singapore. ACE was set up in 2015 as the national HTA Agency and its role has since expanded to beyond the remit of a HTA agency. I currently supervise the team on strategic planning, corporate finance and administration, as well as the local and international collaborations for ACE’s development. Vanessa Xavier Head Of Market Access, Australia And New Zealand Sanofi Australia [email protected] au.linkedin.com/in/vanessa-xavier-77474587 Vanessa Xavier is the Head of Market Access for Sanofi Australia and New Zealand, with almost 20 years experience developing and implementing successful reimbursement strategies which have helped to support affordable access for patients to a broad range of treatments. A Pharmacy graduate, she commenced her career in Market Access in the UK, where she completed a Masters in Public Health at the London School of Hygiene and Tropical Medicine. She continued her career in Australia where she completed a Masters degree in Economics at Macquarie University Australia and had the opportunity to undertake a secondment in Canada to learn more about access policies and processes in another country which has adopted health technology assessment to inform investment decisions related to healthcare interventions. At Sanofi we chase the miracles of science to improve people’s lives and as the Head of Market Access for Australia and New Zealand, Vanessa is committed to working collaboratively with government, healthcare professionals and patients to support timely and affordable access to innovative medicines and vaccines for Australians and New Zealanders. 63
Attendees Di Xue Professor Fudan University China [email protected] Xue, Di, Professor, MD, MPH, Ph.D, Vice director of Key Laboratory of Health Technology Assessment (MOH), School of Public Health, Fudan University. Her main research areas include hospital management, health technology assessment, research bioethics, and health policy analysis. In recent years, she has got the research projects from Natural Science Fund, Shanghai Municipal Government, and some other organizations. Based on the research, she has published many papers on national or international scientific journals in the area of health care management. Kaoru Yamabe Head of Japan Market Access Edwards Lifesciences Japan [email protected] Kaoru Yamabe is the Head of Market Access Japan, Senior Director of JAPAC Market Access, Edwards Lifesciences Corp. Before then had been working for CMIC Corp., Takeda Pharmaceutical Corp., MSD Ltd., as the Head of Healthcare Policy & Access for around twenty years. Wen-wen Yang Researcher, TWNHCP Office Ministry Of Health And Welfare Taiwan [email protected] Wen-Wen Yang is a Researcher in the Taiwan National Hepatitis C Program Office, Ministry Of Health And Welfare. Her work and primary interests include clinical effectiveness, systematic reviews, patient involvement, and health technology assessment. 64
ASIA POLICY FORUM Taipei, Taiwan Renaissance Taipei Shihlin Hotel November 1 - 3, 2023 #2023APF
HTAi 2023 ANNUAL MEETING ADELAIDE AUSTRALIA THE ROAD TO POLICY AND CLINICAL INTEGRATION SAVE THE DATE June 24-28,2023 htai2023.org #HTAi2023Adelaide
WANT TO GET MORE INVOLVED IN A WORKING GROUP OR PROJECT? Join an HTAi Interest Group! Did you know: • HTAi has 10 different Interest Groups • 60% of HTAi members belong to one or more Interest Group • Fosters project collaboration, facilitates the exchange of information, and sets the stage for networking on small-scale initiatives through to engagement in larger, multi-stakeholder international projects Involvement in the IGs is open to all HTAi members with current membership, allowing you to keep up with IG activities and opportunities to get more involved in specific working groups and projects. Want more info? Visit https://htai.org/interest-groups
1200, 10405 Jasper Avenue, Edmonton, Alberta, Canada T5J 3N4 Tel: 780.448.4881 Fax: 780.448.0018 E-mail: [email protected] Twitter: twitter.com/HTAiOrg Facebook: facebook.com/HTAiOrg LinkedIn: linkedin.com/company/htai www.HTAi.org
Search
